title: [Survival of patients with metastatic breast cancer according to pathological types of tumors].
abstract: BACKGROUND
  The prognosis of breast cancer (BC) is in part determined by the stage at diagnosis and its pathological characteristics.
  
  
  OBJECTIVE
  To evaluate the association between survival of women with metastatic breast cancer and pathological features of the tumor.
  
  
  METHODS
  We obtained clinical and pathological data from patients diagnosed with a metastatic BC between 1999 and 2013. The expression of estrogen (ER) and progesterone (PR) receptors and human epidermal growth factor receptor 2 (HER2) was determined by immunohistochemistry. Clinicopathological subtypes were defined as: Luminal A: ER or PR positive, HER2 negative, histological grade (HG) 1 or 2; Luminal B: ER or PR positive, HER2 negative or positive or HG 3; triple negative (TN): ER, PR and HER2 negative, independent of the HG, positive HER2: ER, PR negative and HER2 positive, independent of HG. We analyzed survival based on these subtypes.
  
  
  RESULTS
  We identified 54 patients aged 24 to 85 years, with metastatic BC at diagnosis. Seventy five percent had luminal tumors; 19.6% HER2 positive and 7.8% were TN. In 61% of evaluable tumors, HG was classified as 3. The frequency of HER2 positive and high HG tumors was greater in these patients with metastatic BC than in a non-metastatic local BC cohort. Survival was higher among patients with Luminal tumors than in women with non-Luminal cancer (56.4 and 11.4 months, respectively, p = 0.04).
  
  
  CONCLUSIONS
  Patients with metastatic BC at diagnosis often had HER2 positive tumors and high HG. As in other studies, ER positive tumors had a better survival.
authors.forename: César
authors.initials: C
authors.lastname: Sánchez R
authors.forename: Francisco
authors.initials: F
authors.lastname: Acevedo C
authors.forename: Militza
authors.initials: M
authors.lastname: Petric G
authors.forename: Héctor
authors.initials: H
authors.lastname: Galindo A
authors.forename: Francisco
authors.initials: F
authors.lastname: Domínguez C
authors.forename: Augusto
authors.initials: A
authors.lastname: León R
authors.forename: Dravna
authors.initials: D
authors.lastname: Razmilic V
authors.forename: Carolina
authors.initials: C
authors.lastname: Ceballos
authors.forename: Fernando
authors.initials: F
authors.lastname: Espinoza
authors.forename: M Elena
authors.initials: ME
authors.lastname: Navarro O
authors.forename: David
authors.initials: D
authors.lastname: Oddó B
authors.forename: Mauricio
authors.initials: M
authors.lastname: Camus A
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000737:chemistry / Q000145:classification / Q000401:mortality* / Q000473:pathology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human